A Comprehensively Prognostic and Immunological Analysis of PARP11 in Pan-cancer

Shengli Wang; Mingyue Zhang; Tao Li; Xinru Chen; Qinhan Wu; Dan Tian; Zvi Granot; Hongbiao Xu; Jianlei Hao; Hongru Zhang

doi:10.1093/jleuko/qiae030

A Comprehensively Prognostic and Immunological Analysis of PARP11 in Pan-cancer

J Leukoc Biol. 2024 Feb 9:qiae030. doi: 10.1093/jleuko/qiae030. Online ahead of print.

Authors

Shengli Wang^{1

2}, Mingyue Zhang^{1

2}, Tao Li^{1

2}, Xinru Chen^{1

2}, Qinhan Wu³, Dan Tian⁴, Zvi Granot⁵, Hongbiao Xu⁶, Jianlei Hao^{1

2}, Hongru Zhang³

Affiliations

¹ Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, Guangdong, P.R. China.
² The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, 510632, Guangdong, P.R. China.
³ College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
⁴ Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, P.R. China.
⁵ Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University Medical School, Jerusalem, Israel.
⁶ Department of Thyroid and Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshaner St, Guangzhou, 510275, Guangdong, P.R. China.

PMID: 38334307
DOI: 10.1093/jleuko/qiae030

Abstract

Poly (ADP ribose) polymerase family member 11(PARP11) has important immune regulatory functions in viral infection and tumor immune response. Particularly, PARP11 showed protumor activities in multiple preclinical murine models. However, no systematic pan-cancer analysis has been conducted to explore PARP11 function. In this study we used multiple databases to assess PARP11 expression, which associations with clinical outcomes, immune checkpoint factors, prognostic significance, genomic characteristics, and immunological aspects. The analysis revealed varying expression levels of PARP11 across different cancer types and a significant correlation between its expression and immune cell infiltration. Insights from the CellMiner database suggest a strong link between PARP11 expression and sensitivity to anticancer drugs, highlighting its potential as a therapeutic target. Moreover, PARP11 expression correlates with patient survival during anti-PD1 and anti-CTLA4 treatments, suggested that PARP11 would be a predictor of immune checkpoint inhibitor (ICI) treatment. In summary, PARP11 would be a potential immunoregulatory target and a diagnosis and prognosis marker for certain types of cancers. The detailed mechanisms of PARP11 in tumor immune responses need to be further investigated.

Keywords: Immunotherapy; PARP11; immune cell infiltration; prognosis.